PROMETHERA Biosciences S.A./N.V.

41 articles about PROMETHERA Biosciences S.A./N.V.

• Promethera® Announces Changes in Executive Leadership

  9/2/2020

  Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, based in Wallonia, Belgium, announced that John Tchelingerian, PhD, has resigned from his position as Chief Executive Officer and member of the Board of Directors, effective 27 August 2020.

• Promethera® Plans to Form Joint Venture to Conduct Research and Develop Cell-Based and Biological Therapies for the Treatment of Liver Diseases in China and Southeast Asia With Hao Tian Development

  7/16/2020

  Promethera® Biosciences S.A., global innovator in cell-based medicines and liver diseases, and Hao Tian Development Group Limited a diversified investment holding company, through its subsidiary Aceso Life Science Holding Limited, announced that the companies have entered into an agreement to form a joint venture.

• Promethera® Announces Changes in Management Team

  3/30/2020

  Promethera ® Announces Changes in Management Team

• Promethera® Announces Initiation of Phase 2b DHELIVER Study of HepaStem™ in Patients with Acute-on-Chronic Liver Failure (ACLF)

  1/8/2020

  Potentially pivotal trial for industry’s most-advanced cell-based therapy in severe liver diseases expected to generate results in H2 2023

• Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D

  12/16/2019

  Promethera® Biosciences SA announced the addition of €7.5 million to its recent €39.7 million Series D financing led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures.

• Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL HOLDINGS

  11/12/2019

  Bringing Innovative Liver-Focused Cell Therapies to Japanese Markets

• Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

  5/9/2019

  PANASH Trial will Evaluate Safety and Early Signs of Efficacy of HepaStem® in F3- F4-grade NASH Patients

• Promethera Biosciences Completes €39.7 Million ($44.4 Million) Series D Financing

  5/7/2019

  Proceeds will support ongoing clinical evaluation of HepaStem® in ACLF and launch of a clinical trial in late stage NASH set to commence in H1 2019 in Europe with significant further expansion into the US and Asia

• Promethera Biosciences Presents Updated Phase 2a Results for World’s First Stem Cell Clinical Trial in ACLF at The International Liver Congress™/ EASL 2019

  4/15/2019

  Interim safety results and early efficacy signals with HepaStem bode well for subsequent confirmatory trials in ACLF and provide valuable insights for imminent start of clinical evaluation in NASH

• Promethera Biosciences Announces Late-Breaking Data Presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF

  3/27/2019

  Interim safety data together with early signals of efficacy will be presented in oral presentation at The International Liver Congress™

• Promethera Biosciences to Attend and Present at Upcoming Scientific and Partnering Conferences in March and April

  3/12/2019

  Promethera Biosciences SA announced that the Company will give presentations and attend the following scientific and partnering conferences in Japan, Europe, and the US.

• Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets

  1/2/2019

  First anchor investor in upcoming Series D financing round commits EUR10 million and intends to support Promethera broadly in R&D, BD and through its Medical Network in Asia

• Promethera Biosciences Appoints Mutsuki Takano to Group Chief Financial Officer

  10/5/2018

  Promethera Biosciences SA today announced that Mutsuki Takano, currently Branch General Manager of Promethera Biosciences Japan Branch and Member of the Management Team of Promethera Biosciences SA will succeed Frank Hazevoets as Group Chief Financial Officer (Group CFO), in addition to his current responsibilities.

• cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada

  8/29/2018

  Promethera Biosciences SA today announced that Health Canada has confirmed a cGMP compliance status for the company’s production facility in Durham, North Carolina.

• Promethera Biosciences Appoints Mutsuki Takano as General Manager of its Branch Office in Tokyo

  7/30/2018

  Promethera Biosciences SA announced the appointment of Mutsuki Takano as Branch General Manager of Promethera Biosciences Japan Branch and Member of the Management Team of Promethera Biosciences SA.

• Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model

  4/12/2018

  Poster Presentation at EASL 2018 Builds on Previous Data Confirming HepaStem’s Therapeutic Potential Across Different Stages of the Disease

• Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidate

  4/10/2018

  Transaction Underpins Promethera’s Commitment to Become the Leading Drug Developer in Severe Liver Diseases

• Promethera Biosciences Announces Updates to its Board of Directors Charles L. Dimmler, III elected as new Chairman of the Board

  4/6/2018

  “We welcome Charles, Masaki and Reiko as highly accomplished pharma and life sciences industry leaders, who will help us expand our corporate, deal-making and product development strategies,” said John Tchelingerian, President & CEO of Promethera

• Promethera Biosciences Provides Update on Executive Management Team

  11/22/2017

  The two hires both have more than 20 years of experience in the field of cell therapy.

• PROMETHERA Biosciences S.A./N.V. And Shibuya Announce Strategic Collaboration To Establish Breakthrough Cell Therapy Manufacturing Platform

  10/5/2017